Icon

COZAAR (nda020386)- (25MG,50MG,100MG)

LOSARTAN POTASSIUM ORGANON
25MG,50MG,100MG
Yes No
2014-Sep-04 Expired
None None
None No
COZAAR is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
19 0 14
Total Other Developers 15
Drugs with Suitability No
25MG ** ** - - 12
50MG ** ** Up - 13
100MG ** ** Up - 12
NDA Sales Available Total Generic Sales Available
Yes 12
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***
****** ***** *** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ***** *** ***** ******* *********** ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ********* ****** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ******* ******* ******* *********** **** **. ***, ***, ***, *** & ***, ***** ************** *******, *******, ************, ***** **** ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***
****** ******** ******* ******** ******* *************** ***. *********** *** ***** *****, *********, ******** (**) *****, ****** ****** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** *** *** ************ ******* ******* *********** *********** ********, **** -** **. **'* (***** **) : ***, *** , ***, ***, ***, ***, ***, ***- *** *** *** ******** (*******), ********* (******),, ********** (********), ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******** ******** *************** ***. *********** **** & **** ******** *******, *********, ******** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.